Drug Combinations

"Drug Combinations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.

Descriptor ID	D004338
MeSH Number(s)	D26.310
Concept/Terms	Drug Combinations Drug Combinations Combinations, Drug

Below are MeSH descriptors whose meaning is more general than "Drug Combinations".

Chemicals and Drugs [D]
Pharmaceutical Preparations [D26]
Drug Combinations [D26.310]

Below are MeSH descriptors whose meaning is more specific than "Drug Combinations".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Combinations" by people in this website by year, and whether "Drug Combinations" was a major or minor topic of these publications.

Bar chart showing 132 publications over 27 distinct years, with a maximum of 14 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1996	0	3	3
1999	0	2	2
2000	0	3	3
2002	0	2	2
2003	0	4	4
2004	0	6	6
2005	0	5	5
2006	0	5	5
2007	0	5	5
2008	0	1	1
2009	0	3	3
2010	0	4	4
2011	0	7	7
2012	0	3	3
2013	0	5	5
2014	0	6	6
2015	0	3	3
2016	0	6	6
2017	0	10	10
2018	0	5	5
2019	0	7	7
2020	0	14	14
2021	0	6	6
2022	0	11	11
2024	1	3	4
2025	0	1	1

Below are the most recent publications written about "Drug Combinations" by people in Profiles.

Sun W, Weng W, Shi J, Ma B, D DeMarco K, Gui F, Jin R, Ruscetti M, Jia L, Hu W, Shi Y, Meng X. SPARC: A Multipayload ADC Architecture for Programmable Drug Combinations. Bioconjug Chem. 2025 Oct 15; 36(10):2158-2171.

View in: PubMed
Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, Francis F, Buguzi CC, Moshi R, Garimo I, Lazaro S, Lusasi A, Aaron S, Chacky F, Mohamed A, Njau RJA, Kitau J, Rasmussen C, Bailey JA, Juliano JJ, Warsame M. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. Lancet Infect Dis. 2024 Nov; 24(11):1225-1233.

View in: PubMed
Juliano JJ, Giesbrecht DJ, Simkin A, Fola AA, Lyimo BM, Pereus D, Bakari C, Madebe RA, Seth MD, Mandara CI, Popkin-Hall ZR, Moshi R, Mbwambo RB, Niar? K, MacInnis B, Francis F, Mbwambo D, Garimo I, Chacky F, Aaron S, Lusasi A, Molteni F, Njau RJA, Nhiga SL, Mohamed A, Bailey JA, Ishengoma DS. Prevalence of mutations associated with artemisinin partial resistance and sulfadoxine-pyrimethamine resistance in 13?regions in Tanzania in 2021: a cross-sectional survey. Lancet Microbe. 2024 Oct; 5(10):100920.

View in: PubMed
Mitchell CL, Janko MM, Verity R, Kashamuka MM, Bailey JA, Tshefu AK, Parr JB, Juliano JJ. Close Proximity to Mining Is Associated with Increased Prevalence of the Drug Resistance-Associated Mutation dhps540E in Eastern Democratic Republic of the Congo. Am J Trop Med Hyg. 2024 Aug 07; 111(2):361-364.

View in: PubMed
Som? AF, Conrad MD, Kabr? Z, Fofana A, Yerbanga RS, Bazi? T, Neya C, Som? M, Kagambega TJ, Legac J, Garg S, Bailey JA, Ou?draogo J-B, Rosenthal PJ, Cooper RA. Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrob Agents Chemother. 2024 04 03; 68(4):e0153423.

View in: PubMed
Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P. Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022; 17:3061-3073.

View in: PubMed
Bardsley S, Criner GJ, Halpin DMG, Han MK, Hanania NA, Hill D, Lange P, Lipson DA, Martinez FJ, Midwinter D, Siler TM, Singh D, Wise RA, van Zyl-Smit RN, Berkman N. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med. 2022 12; 205:107040.

View in: PubMed
Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T, Legac J, Garg S, Giesbrecht D, Smith SR, Ceja FG, Nsobya SL, Bailey JA, Cooper RA, Rosenthal PJ. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun. 2022 10 26; 13(1):6353.

View in: PubMed
Thompson PJ, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lipson DA, Maghzal GJ, Martinez FJ, Midwinter D, Singh D, Tombs L, Wise RA. Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial. Respirology. 2022 12; 27(12):1034-1044.

View in: PubMed
Dosoo DK, Bailey JA, Asante KP, Oppong FB, Niar? K, Opoku-Mensah J, Owusu-Agyei S, Greenwood B, Chandramohan D. The prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine among pregnant women at first antenatal clinic attendance and delivery in the forest-savannah area of Ghana. PLoS One. 2022; 17(8):e0271489.

View in: PubMed

People

Explore

Similar Concepts

Top Journals